250
Participants
Start Date
March 11, 2025
Primary Completion Date
May 31, 2032
Study Completion Date
September 30, 2032
BMS-986489
BMS-986489 (fixed dose combination of atigotatug + nivolumab) will be administered as an intravenous infusion to be given once every 4 weeks for up to 2 years.
Durvalumab
Durvalumab will be administered as a fixed dose intravenous infusion to be given once every 4 weeks for up to 2 years.
RECRUITING
Virginia Cancer Specialists, Fairfax
RECRUITING
Virginia Oncology Associates, Norfolk
RECRUITING
Blue Ridge Cancer Center (Oncology & Hematology Associates of Southwest VA), Salem
RECRUITING
Florida Cancer Specialists - North, Orange City
RECRUITING
Cancer Care Centers of Brevard, Palm Bay
RECRUITING
Florida Cancer Specialists - East, West Palm Beach
RECRUITING
Florida Cancer Specialists - South, Fort Myers
RECRUITING
Ocala Oncology Center, Ocala
RECRUITING
Southern Cancer Center, Daphne
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
Tennessee Cancer Specialists, Knoxville
RECRUITING
Mid Ohio Hem/ Onc dba The Mark H Zangmeister Center, Columbus
RECRUITING
Oncology Hematology Care, Cincinnati
RECRUITING
Minnesota Oncology Hematology, Maple Grove
RECRUITING
Illinois Cancer Specialists, Arlington Heights
RECRUITING
Illinois Cancer Care, Peoria
RECRUITING
Texas Oncology - DFW, Dallas
RECRUITING
Texas Oncology - Northeast Texas, Tyler
RECRUITING
Texas Oncology - Gulf Coast, Beaumont
RECRUITING
Texas Oncology - San Antonio, San Antonio
RECRUITING
Texas Oncology - West Texas, Amarillo
RECRUITING
Sansum Clinic, Santa Barbara
RECRUITING
Oncology Associates of Oregon (Willamette Valley Cancer Institute and Research Center), Eugene
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
SCRI Development Innovations, LLC
OTHER